

The vaccines for the pandemic virus are not just for preventing the spread… They are also a significant source of revenue now and coming.
Millions upon millions of dosages have been manufactured and sold to governments and private healthcare companies, creating major flows of revenue for the leaders in the market.
Johnson & Johnson (JNJ), AstraZeneca PLC (AZN) and others have gone the traditional route to vaccine development – utilizing existing technologies that have been deployed for other situations, including the annual influenza threats.
Then, there is the next level development involving messenger ribonucleic acid (mRNA) that’s been led by Pfizer Inc. (PFE) and its partner BioNTech SE (BNTX) as well as Moderna, Inc. (MRNA).
This newer technology is not just for the current virus, however, as it sets up a whole new world of potential treatments of a wider variety of health threats. In turn, this means that the companies behind this rapidly developing and evolving technology will potentially have new pipelines of products and treatments.
The vaccine market is just one part of the overall drug and treatment development market. There are countless companies from the early stage to the mega-cap establishment that are at work 24/7 in laboratories working on a myriad of cures.
And what comes out of these laboratories are of course alchemy products. They take basic building blocks of chemicals and medicines and, with technology, create billions of dollars of drugs and treatments.
Dow Jones US Biotechnology Index -- Source: Dow Jones
Biotechnology is one of the ongoing super-charged segments of the market. The companies inside this segment can go not just from zero to hero for patients around the globe – but they also can deliver huge gains for their shareholders.
The Company Behind All of This
All of the above companies as well as countless others rely on laboratories. These are highly specialized facilities. They need to be highly secure in terms of their environment, including water, natural gas and other inputs – including controlled and filtered air.
These are not just found in generic office parks. They need to be built specifically – or heavily modified from specific existing buildings to meet the standards needed for drug development companies.
And they tend to be collected around each other. They also tend to be collected around leading academic and research facilities – especially at major universities. They all need brainiacs to do the work, and they also need government grants and support that tend to be found in academic settings.
The company that is the leader in this market is Alexandria Real Estate Equities, Inc. (ARE). This is the Pasadena, California-based company that’s set up as a real estate investment trust (REIT) that owns primary laboratories and related facilities in the key and core clustered areas for drug and biotechnology development.
Alexandria Real Estate Equities, Inc. Price -- Source: Dow Jones
Most of the leaders in this market depend on Alexandria Real Estate to build and develop their laboratories and other required facilities and lease them for their must-have space.
Don’t just think about it as a REIT or an office building owner. Just as folks got rich ages ago selling picks and shovels during the gold rush, you can think of this company as the ultimate “picks and shovels” stock providing the necessities for drug and biotechnology companies.
That is what makes this company a compelling buy right now behind the scenes.
As always, I want to hear from you as an Insider here at Traders Agency.
This includes your thoughts on our work here and what we should be covering and how to improve our services to you.
I can be reached directly at [email protected].
All my best,
P.S. My colleague and expert trader Ross Givens has exposed a little-known SEC loophole that allows corporate insiders to buy and sell their own stocks 100% legally.
Obviously, these folks have privileged knowledge about their companies… And they use that knowledge to trade their own companies’ stocks with impeccable timing.
Now, you can too, but only if you act before this opportunity runs out!
If you’re ready to take your trading to the next level and learn to profit alongside company insiders, click here now.
Contact
Courses
About Us
Sign up
Login
Educational Purposes
We (“Traders Agency”) are a provider of educational products that we believe will assist you in trading commodity futures profitably. We do not provide any guarantees, warranties or assurances that by using our educational products, you will be successful in trading commodity futures profitably. The information contained on our website or in any product or service provided by us does not constitute financial advice or a solicitation to buy or sell any commodity futures, currencies, including cryptocurrency, options or securities. We are not a commodity trading advisor, a futures commission merchant, a commodity pool operator, a broker or an investment advisor. We do not make investment recommendations and we do not trade commodity futures or any other investment for our customers. We do not hold customer funds for trading commodity futures or any other investment. You agree that you will not hold us responsible for any losses you may incur in trading commodity futures while relying upon our educational products.
Risk Disclosure Statement
The risk of loss in trading commodity futures contracts can be substantial. You should, therefore, carefully consider whether such trading is suitable for you in light of your circumstances and financial resources. Under certain market conditions, you may find it difficult or impossible to liquidate a position. This can occur, for example, when the market reaches a daily price fluctuation limit (“limit move”). The high degree of leverage (gearing) that is often obtainable in futures trading because of the small margin requirements can work against you as well as for you. Leverage (gearing) can lead to large losses as well as gains. You may sustain a total loss of the funds that you deposit with your broker to establish or maintain a position in the commodity futures market, and you may incur losses beyond these amounts.
Hypothetical or Simulated Results
Our educational products rely upon hypothetical or simulated performance results. These results have certain inherent limitations. Unlike the results shown in an actual performance record, these results do not represent actual trading. Also, because these trades have not actually been executed, these results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated or hypothetical trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profits or losses similar to those shown.
Testimonial Disclosure
We often include testimonials from previous customers who have used our educational products. You should be aware that:
The testimonial may not be representative of the experience of other clients.
The testimonial is no guarantee of future performance or success.
We do not pay or provide any compensation to any person who has provided a testimonial.
Sign in/up with Facebook
Sign in/up with Twitter
Sign in/up with Linkedin
Sign in/up with Google
Sign in/up with Apple
Wouldn't it be a good idea to create a course?